Hematology/Oncology

Top Story

Premature ovarian insufficiency tied to pelvic radiotherapy, alkylating agent exposure

Premature ovarian insufficiency tied to pelvic radiotherapy, alkylating agent exposure
March 30, 2017

Women who had childhood cancer may have an increased risk for premature ovarian insufficiency after treatment with pelvic radiotherapy and alkylating agents, study data show.

Wassim Chemaitilly, MD, associate member and director of the division of endocrinology, at St. Jude Children’s Research Hospital in Memphis, Tennessee, and colleagues evaluated data from the St. Jude Lifetime Cohort Study on 921 female cancer survivors (median age, 31.7 years) evaluated at a median of 24 years after a childhood cancer diagnosis to determine the prevalence of premature ovarian insufficiency, its risk factors and associated long-term adverse health outcomes.

FDA News

FDA grants regular approval to Tagrisso for certain patients with NSCLC

March 30, 2017
The FDA granted regular approval to osimertinib for the treatment of certain patients with metastatic non–small cell lung cancer. The approval allows osimertinib…
Meeting News

HIPEC well tolerated in gastric carcinomas

March 30, 2017
Patients with gastric cancer and positive cytology or low-volume carcinomatosis experienced few postoperative complications after receiving laparoscopic preoperative…
In the Journals

Registry study: Lymphoma risk for patients with rheumatoid arthritis remains increased

March 30, 2017
The risk for malignant lymphoma remained increased for patients with rheumatoid arthritis, according to recently published population-based data for 1997 to 2012. …

Survey: American physicians satisfied with career choice despite challenges

March 30, 2017
A survey of 1,200 American physicians, residents and medical students found that nine out of 10 physicians are satisfied with their career choice despite common…
More News Headlines »
CME

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »
Video
Meeting News

VIDEO: New immune targets may improve advanced melanoma outcomes

March 25, 2017
More »
Featured
HEMONC TODAY Melanoma and Cutaneous Malignancies

HEMONC TODAY Melanoma and Cutaneous Malignancies

CME

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement